Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Diabetes

  Free Subscription


Articles published in Am J Nephrol

Retrieve available abstracts of 12 articles:
HTML format
Text format



Single Articles


    June 2019
  1. COMAI G, Malvi D, Angeletti A, Vasuri F, et al
    Histological Evidence of Diabetic Kidney Disease Precede Clinical Diagnosis.
    Am J Nephrol. 2019 Jun 5:1-8. doi: 10.1159/000500353.
    PubMed     Text format     Abstract available


  2. LEE J, Chu C, Guzman D, Fontil V, et al
    Albuminuria Testing by Race and Ethnicity among Patients with Hypertension with and without Diabetes.
    Am J Nephrol. 2019 Jun 5:1-7. doi: 10.1159/000500706.
    PubMed     Text format     Abstract available


    March 2019
  3. WOODS TC, Satou R, Miyata K, Katsurada A, et al
    Canagliflozin Prevents Intrarenal Angiotensinogen Augmentation and Mitigates Kidney Injury and Hypertension in Mouse Model of Type 2 Diabetes Mellitus.
    Am J Nephrol. 2019;49:331-342.
    PubMed     Text format     Abstract available


  4. BURNS KD, Cherney D
    Renal Angiotensinogen and Sodium-Glucose Cotransporter-2 Inhibition: Insights from Experimental Diabetic Kidney Disease.
    Am J Nephrol. 2019;49:328-330.
    PubMed     Text format    


    January 2019
  5. RUGGENENTI P, Remuzzi G
    Albuminuria Regression in Diabetes: A Therapeutic Target for Nephro- and Cardio-Protection, in Clinics and Research.
    Am J Nephrol. 2019;49:143-145.
    PubMed     Text format    


  6. ANYANWAGU U, Donnelly R, Idris I
    Albuminuria Regression and All-Cause Mortality among Insulin-Treated Patients with Type 2 Diabetes: Analysis of a Large UK Primary Care Cohort.
    Am J Nephrol. 2019;49:146-155.
    PubMed     Text format     Abstract available


    May 2018
  7. YAMAMOTO CM, Murakami T, Oakes ML, Mitsuhashi M, et al
    Uromodulin mRNA from Urinary Extracellular Vesicles Correlate to Kidney Function Decline in Type 2 Diabetes Mellitus.
    Am J Nephrol. 2018;47:283-291.
    PubMed     Text format     Abstract available


    January 2018
  8. CHIN MP, Bakris GL, Block GA, Chertow GM, et al
    Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study.
    Am J Nephrol. 2018;47:40-47.
    PubMed     Text format     Abstract available


  9. TRIEBSWETTER S, Gutjahr-Lengsfeld LJ, Schmidt KR, Drechsler C, et al
    Long-Term Survivor Characteristics in Hemodialysis Patients with Type 2 Diabetes.
    Am J Nephrol. 2018;47:30-39.
    PubMed     Text format     Abstract available


    December 2017
  10. JARDINE MJ, Mahaffey KW, Neal B, Agarwal R, et al
    The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics.
    Am J Nephrol. 2017;46:462-472.
    PubMed     Text format     Abstract available


  11. NEUMILLER JJ, Rhee CM, Kalantar-Zadeh K
    Will Canagliflozin Lend Credence to the Potential Effects of Sodium-Glucose Co-Transporter 2 Inhibitors on Renal Endpoints in Diabetic Nephropathy.
    Am J Nephrol. 2017;46:459-461.
    PubMed     Text format    


    September 2017
  12. SAULNIER PJ, Dieter BP, Tanamas SK, McPherson SM, et al
    Association of Serum Amyloid A with Kidney Outcomes and All-Cause Mortality in American Indians with Type 2 Diabetes.
    Am J Nephrol. 2017;46:276-284.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Diabetes is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: